SCHEMBL7486923

SCHEMBL7486923

N#Cc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)c(NS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDH2 P48735 14/20 0.61
IDH1 O75874 1/20 0.58
MEN1 O00255 2/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 2/20 0.54
KMT2A Q03164 2/20 0.54
LMNA P02545 1/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 1/20 0.54
XBP1 P17861 1/20 0.54
ALOX12 P18054 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
RAB9A P51151 1/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
GRIK1 P39086 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7555940 0.84 SLC22A12 (0.52) IDH2MEN1KMT2APOLBGRIK1
SCHEMBL7595568 0.81 MEN1 (0.54) MEN1KMT2ALMNANPSR1CA1
SCHEMBL7496445 0.80 ACLY (0.52) IDH2MEN1MAPTKMT2ALMNA
SCHEMBL5595140 0.80 CXCR1 (0.69) IDH1MEN1MAPTHTTKMT2A
SCHEMBL7492157 0.79 IDH2 (0.48) IDH2IDH1MEN1MAPTKMT2A
SCHEMBL7940030 0.78 HDAC1 (0.50)
SCHEMBL3709166 0.78 CXCR2 (0.63) MEN1HTTKMT2ALMNARAB9A
SCHEMBL7490402 0.78 GPR27 (0.51) MEN1MAPTKMT2ALMNACA12
SCHEMBL7487824 0.78 TBXA2R (0.50) IDH2HTTPOLBNPSR1CA12
SCHEMBL7491182 0.78 GPR27 (0.51) MEN1MAPTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0896531-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-30 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
EP-0896531-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-17 EP disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN IDH2 4348/4885IDH1 4570/4885MEN1 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.